Hey GoodGuyBill, that IT agreement I posted for you as an example of a proper transparent arrangement now comes with this PR too. Have you ever seen similar copy in a PR coming from NWBO about UCLA?
>>Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors. A research team from Baylor College of Medicine has now published groundbreaking work in Nature Medicine investigating Multi-Antigen Targeted T cells in patients with pancreatic cancer.
Market Data 
Markets 
AI
